NEW YORK, Aug. 9 /PRNewswire-Asia-FirstCall/ -- American
Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or
"AOBO"), a pharmaceutical company dedicated to improving health
through the development, manufacture and commercialization of a
broad range of prescription and over the counter ("OTC") products,
today announced the commercial launch of Boke brand Yi Shen Jian Gu
Gel ("YSJG" Gel) after successful test marketing in the second
quarter of 2010.
Boke YSJG Gel aims at alleviating osteoporosis. A report issued
by China's Ministry of Health
("MOH") shows that between 35 and 40 million people in China, or about 3% of the population, have
osteoporosis, and the number of patients is expected to increase to
150 million by the year 2025.
The main active ingredient of YSJG Gel is Rhizoma Homalomenae,
as well as ginseng, safflower, and fleece flower root, and is
granted proprietary status by China's SFDA.
Mr. Tony Liu, Chairman and CEO of
AOBO, commented, "The addressable market is large and growing for
this product. We intend to make use of YSJG's proprietary drug
status and Boke's brand image in our marketing."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over the counter products.
Forward-Looking Statements
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties that may cause actual results to differ materially
from those set forth in these statements. The economic,
competitive, governmental, technological and other factors
identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-K for the year ended
December 31, 2010, may cause actual
results or events to differ materially from those described in the
forward looking statements in this press release. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information,
future events, or otherwise.
For more information, please contact:
ICR, LLC
Christine Duan or Ashley Ammon
Phone: +1-646-277-1200
SOURCE American Oriental Bioengineering, Inc.
Copyright g. 9 PR Newswire